Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06157151 · ClinicalTrials.gov registry record · Phase 2
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
A Phase 2 study of Cervical Cancer and HPV-Related Carcinoma, sponsored by Precigen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 3
- Study locations
NCT06157151 is a Phase 2 study of Cervical Cancer and HPV-Related Carcinoma that is actively recruiting participants, run by Precigen. The registered enrollment target is 46 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06157151, a Phase 2 study of Cervical Cancer and HPV-Related Carcinoma, is actively recruiting participants, sponsored by Precigen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 3
- Study locations
Study Summary
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Conditions Studied
Interventions
- BIOLOGICAL PRGN-2009 plus Pembrolizumab
- DRUG Pembrolizumab alone
Study Locations (3)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Maryland
- National Institute of Health - Bethesda
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2028-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06157151
The ClinicalTrials.gov registry entry for NCT06157151 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Precigen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which PRGN-2009 plus Pembrolizumab is the first listed.
NCT06157151 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arkansas, Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT06157151 about?
NCT06157151 is a clinical study titled "PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer". This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
What is the current status of trial NCT06157151?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2025-03-21. Estimated completion is 2028-01-30.
What conditions does trial NCT06157151 study?
This clinical trial studies the following conditions: Cervical Cancer, HPV-Related Carcinoma, Recurrent Cervical Carcinoma, HPV-Related Malignancy, Metastatic Cervical Cancer.
What interventions are being tested in trial NCT06157151?
The interventions under investigation include: PRGN-2009 plus Pembrolizumab (BIOLOGICAL), Pembrolizumab alone (DRUG).
Who is sponsoring clinical trial NCT06157151?
This trial is sponsored by Precigen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06157151 being conducted?
This trial has 3 study locations across Arkansas, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.